Johnson & Johnson stock ends the day 0.86 percent higher at the close
Published on 09/21/2026 at 22:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson stock closed at USD 269.99 on the NYSE on September 21, 2026, gaining 0.86 percent from the prior close. Compared with the broader U.S. market, the shares outperformed as the S&P 500 rose less on the day, underscoring demand for large healthcare names after the latest trial update.
Trial success lifts September 21, 2026 session
Johnson & Johnson Inc. (ISIN US4781601046, NYSE: JNJ) benefited from a positive clinical update on its psychiatric drug CAPLYTA during the session. The company reported in a press release that CAPLYTA met the primary endpoint in a pivotal Phase 3 study for manic episodes in adults with bipolar I disorder, showing significant and rapid improvement in symptoms according to topline data, as Morningstar relayed from the company.
Per NYSE data cited by MarketScreener, the shares ended the regular session at USD 269.99 after trading within a daily range that kept the close comfortably inside the 52-week band and near an average analyst target around the mid-270s. The percentage gain left the stock ahead of the recent five-day performance and well above its year-start level, while intraday prints later in extended trading showed the stock changing hands above USD 271 at 5:10 p.m. ET, indicating continued interest after the bell.
After the bell and next-day focus
After the close today, attention stays on follow-up data and potential regulatory milestones for CAPLYTA in bipolar mania, as the late-stage success positions the drug for an expanded label according to Reuters. In after-hours trading the stock was last quoted around USD 272.30 at 5:10 p.m. ET on Cboe BZX data, modestly above the official NYSE close, which reflects ongoing investor reaction to the trial news as reported by MarketScreener. On the next U.S. trading day, investors will watch broader healthcare sentiment and any additional commentary from Johnson & Johnson on timelines for filing bipolar mania data with regulators, as well as sector moves around drug-pricing and clinical-trial headlines that can influence diversified pharma names.
